Board Members Buy $5.1M of Stock at $1.01 in Insider-Led Private Placement
VANI sits 31% above its 52-week low of $0.8.
Summary
Vivani is raising about $5.1 million by selling 5,049,506 shares at $1.01 each to Chairman Gregg Williams and fellow director Aaron Mendelsohn, priced at-the-market under Nasdaq rules. The buyers are insiders, not outside institutions, which is a stronger vote of confidence than a typical discounted placement. The cash matters: the Q3 10-Q filed Nov 12 carried a going-concern warning with runway ending Q1 2027, and management now says the proceeds plus existing cash fund operations into Q3 2027. It follows the Nov 12 SLIM-1 Phase 1 readout, where no NPM-139 participants had treatment-related adverse events versus five of ten on Wegovy, and the company is targeting a Phase 2 weight-maintenance trial in 2027. Closing is expected on or about Nov 23, subject to customary conditions.
At the time of this announcement, VANI was trading at $1.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $91.1M. The 52-week trading range was $0.80 to $1.66. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.